Send Message
Home News

company news about WHO Updates HPV Vaccination Schedule Recommendations

China Hangzhou AllTest Biotech CO.,LTD certification
Customer Reviews
We recently started selling your HCG tests via our Australian partner and have been very impressed with the quality and consistency of the tests. They seem to be superior to our current manufacturer and we also know that you are far more reliable in terms of production times and communication.

—— One customer from Europe

We would like to explore the possibility of switching our HCG tests over to you. We have been reluctant in the past to move everything over to you as it makes us very reliant on you. However, we have always found you to be by far the most reliable of all our Chinese manufacturers and so we feel comfortable strengthening our partnership further

—— One customer from Europe

I like the products and service provided by AllTest. They really take our interest into consideration.

—— Mr John Smith England

My oldest daughter actually has Lyme disease. She spent almost 1 year in a wheelchair because of Lyme. She is doing very well now. I used 2 of the samples. 1 to test my Lyme diagnosed daughter and 1 to test my daughter who does not have Lyme. Your tests worked well. My daughter with Lyme tested positive and the one who does not tested negative.

—— Ms Sheila

Whenever I have the requests,AllTest always give me the satisfied reply at the first time.

—— Mrs Julie Tschetter Belgium

As the old customer of AllTest since 2009, we should thank the great work have been done by AllTest to support us gain more market share and profit

—— Mr Robin Seifert Germany

I'm Online Chat Now
Company News
WHO Updates HPV Vaccination Schedule Recommendations
Latest company news about WHO Updates HPV Vaccination Schedule Recommendations

WHO Updates HPV Vaccination Schedule Recommendations


Human Papillomavirus (HPV) is the most common sexually transmitted infection in the United States. The virus is transmitted through intimate skin-to-skin contact. HPV infection is very common, and almost all men and women will be infected with at least one type of HPV at some point in their lives. most infections are asymptomatic and become undetectable, but some infections may be persistent and may develop into cancer in women and men later in life.


HPV infections that do not go away can cause:


  • Cervical, vaginal, and vulvar cancers (in women)
  • Penile cancer (in men)
  • Anal cancer
  • Cancer of the back of the throat (oropharynx)
  • Genital warts


In a new position paper published last week, WHO has updated its recommendations for human papillomavirus vaccines. Of particular note, the paper states that a single-dose schedule (known as an alternative, supra-indicated single-dose schedule) could provide comparable efficacy and durable protection to a two-dose regimen. The WHO Independent Expert Advisory Group SAGE originally proposed an alternative single-dose schedule in April 2022.


The position paper is timely in the context of a severe decline in global HPV vaccination coverage, which declines by 25% to 15% between 2019 and 2021 for the first dose of HPV vaccine. This means that more than 3.5 million girls miss out on HPV vaccination in 2021 compared to 2019.


Optimization of the HPV schedule is expected to improve access to the vaccine, provide countries with the opportunity to expand the number of girls who can be vaccinated, and reduce the burden of the often complex and costly follow-up required to complete the vaccination series. It is critical that countries strengthen their HPV vaccination planning to accelerate implementation and reverse the trend of declining coverage.


WHO now recommends :


One or two doses for girls aged 9-14 years

Girls and women aged 15-20 years need one or two doses

Two doses 6 months apart for women aged >21 years

The position paper emphasizes the importance of prioritizing vaccination for people who are immunocompromised or HIV-infected. Immunocompromised individuals should receive at least two doses and if possible three doses.


The primary target for vaccination is girls aged 9-14 years prior to the initiation of sexual activity. Where feasible and affordable, vaccination of secondary targets such as boys and older women is recommended.


Cervical cancer is the fourth most common cancer in women, and more than 95% of cervical cancers are caused by sexually transmitted HPV. Avoiding the development of cervical cancer by increasing access to an effective vaccine is a very important step in mitigating unnecessary disease and death.

Pub Time : 2023-01-16 11:08:03 >> News list
Contact Details
Hangzhou AllTest Biotech CO.,LTD

Contact Person: Mrs. Selina

Tel: 86-13989889852

Send your inquiry directly to us (0 / 3000)